ES2122964T3 - Sitio de union de icam-1 para mac-1. - Google Patents

Sitio de union de icam-1 para mac-1.

Info

Publication number
ES2122964T3
ES2122964T3 ES91119894T ES91119894T ES2122964T3 ES 2122964 T3 ES2122964 T3 ES 2122964T3 ES 91119894 T ES91119894 T ES 91119894T ES 91119894 T ES91119894 T ES 91119894T ES 2122964 T3 ES2122964 T3 ES 2122964T3
Authority
ES
Spain
Prior art keywords
icam
mac
union site
union
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91119894T
Other languages
English (en)
Inventor
Michael S Diamond
Donald E Staunton
Timothy A Springer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Immune Disease Institute Inc
Center for Blood Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Disease Institute Inc, Center for Blood Research Inc filed Critical Immune Disease Institute Inc
Application granted granted Critical
Publication of ES2122964T3 publication Critical patent/ES2122964T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ropes Or Cables (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Package Frames And Binding Bands (AREA)
  • Hall/Mr Elements (AREA)

Abstract

LA INVENCION ACTUAL SE REFIERE A LA ADHESION INTERCELULAR DE MOLECULAS (ICAM-1) Y A SU INTERACCION CON LA MOLECULA RECEPTORA MAC-1. LA INVENCION SE REFIERE AL USO DE ESTAS MOLECULAS Y DE SUS EQUIVALENTES FUNCIONALES EN EL TRATAMIENTO DE LAS ENFERMEDADES INFLAMATORIAS Y VIRICAS.
ES91119894T 1990-11-28 1991-11-21 Sitio de union de icam-1 para mac-1. Expired - Lifetime ES2122964T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/618,286 US5288854A (en) 1990-11-28 1990-11-28 Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1

Publications (1)

Publication Number Publication Date
ES2122964T3 true ES2122964T3 (es) 1999-01-01

Family

ID=24477094

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91119894T Expired - Lifetime ES2122964T3 (es) 1990-11-28 1991-11-21 Sitio de union de icam-1 para mac-1.

Country Status (8)

Country Link
US (1) US5288854A (es)
EP (1) EP0488061B1 (es)
KR (1) KR920009412A (es)
AT (1) ATE172988T1 (es)
DE (1) DE69130445T2 (es)
DK (1) DK0488061T3 (es)
ES (1) ES2122964T3 (es)
NZ (2) NZ260473A (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6797270B1 (en) 1989-03-16 2004-09-28 Center For Blood Research, Inc. Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
ES2134762T3 (es) * 1990-07-20 1999-10-16 Bayer Ag Formas multimericas de proteinas receptoras de rinovirus humanos.
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US5773218A (en) * 1992-01-27 1998-06-30 Icos Corporation Method to identify compounds which modulate ICAM-related protein interactions
CA2144738A1 (en) * 1992-10-09 1994-04-28 Michael Diamond A subpopulation of mac-1 (cd11b/cd18) molecules which mediate neutrophil adhesion to icam-1 and fibrinogen
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
JP4451933B2 (ja) * 1996-12-27 2010-04-14 住友化学株式会社 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法
CA2328725A1 (en) * 1998-04-15 1999-10-21 Brigham & Women's Hospital, Inc. T cell inhibitory receptor compositions and uses thereof
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
CA2417432C (en) 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
US6667318B2 (en) * 2000-11-28 2003-12-23 Genentech, Inc. LFA-1 antagonist compounds
JP5105578B2 (ja) * 2003-11-05 2012-12-26 サーコード バイオサイエンス インコーポレイテッド 細胞接着のモジュレーター
WO2006023491A2 (en) 2004-08-16 2006-03-02 The Cbr Institute For Biomedical Research, Inc. Method of delivering rna interference and uses thereof
US20060233675A1 (en) * 2005-04-13 2006-10-19 Stein Israel M Glass test tube having protective outer shield
US8168655B2 (en) 2005-05-17 2012-05-01 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
EP2020992A2 (en) * 2006-04-24 2009-02-11 The CBR Institute for Biomedical Research, Inc. Method of producing immunoliposomes and compositions thereof
AU2007243412A1 (en) * 2006-04-25 2007-11-08 Immune Disease Institute Inc. Targeted delivery to leukocytes using non-protein carriers
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
EP2265124A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc AEROSOLISED LFA-1 ANTAGONISTS FOR THE USE IN THE LOCAL TREATMENT OF IMMUNE DISEASES
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
JP2011516607A (ja) * 2008-04-15 2011-05-26 サーコード コーポレイション 胃腸系へのｌｆａ−１アンタゴニストの送達
ES2763703T3 (es) * 2008-04-15 2020-05-29 Sarcode Bioscience Inc Antagonistas de LFA-1 tópicos utilizados en el tratamiento localizado de trastornos inmunes
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
SI3715345T1 (sl) 2012-07-25 2024-07-31 Bausch + Lomb Ireland Limited Priprava zaviralca lfa-1
US20170173005A1 (en) 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
WO2022126281A1 (en) 2020-12-18 2022-06-23 Socovar, Société En Commandite Method for manufacturing an electrically conductive composite

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863B1 (en) * 1987-11-02 1994-12-07 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation
ES2141076T3 (es) * 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
DE68929477T2 (de) * 1988-09-28 2004-06-03 Dana-Farber Cancer Institute, Boston Interzellulare Adhäsions-Moleküle und deren Bindungsliganden

Also Published As

Publication number Publication date
NZ260473A (en) 1997-06-24
US5288854A (en) 1994-02-22
EP0488061A2 (en) 1992-06-03
KR920009412A (ko) 1992-06-25
EP0488061B1 (en) 1998-11-04
DE69130445D1 (de) 1998-12-10
ATE172988T1 (de) 1998-11-15
DE69130445T2 (de) 1999-07-08
EP0488061A3 (en) 1992-08-26
NZ240747A (en) 1996-05-28
DK0488061T3 (da) 1999-07-19

Similar Documents

Publication Publication Date Title
DE69130445D1 (de) Die Mac-1-Bindungsstelle von ICAM-1
SE8501709D0 (sv) Improvements in or relating to intrleukin therapy
ES2114870T3 (es) Nuevos derivados de mercaptoacetilamida utiles como inhibidores de encefalinasa y eca.
ES2079373T3 (es) Nuevas azetidinonas sustituidas como agentes antiinflamatorios y antidegenerativos.
DK180278A (da) Anvendelse af proteiner i aromastoffer
ES2139574T3 (es) Nuevos gases propulsores y su uso en preparaciones medicas.
BG29132A3 (en) Method of obtaining of cyclohexan derivatives
ES2059575T3 (es) Aductos modificados de poliepoxido y polioxialquilen-poliamidas.
ES2095380T3 (es) Derivados de indano-2-carboxialquilo sustituidos en la posicion 2 utiles como inhibidores de la encefalinasa y la eca.
ES2044870T3 (es) Un procedimiento para la preparacion de nuevos agentes antihipertensivos.
ES2154741T3 (es) Uso de agentes de union a cd23 en el tratamiento de enfermedades autoinmunes.
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
DE59007288D1 (de) Verwendung des Wirkstoffs Azelastin und Glycerinethern zur Bekämpfung von Psoriasis-Erkrankungen.
ES2177695T3 (es) Uso de derivados funcionales de la molecual de adhesion intercelular icam-1 en terapia antiviral.
DK1032378T3 (da) Anvendelse af en blanding af en diol og en alfa-hydroxysyre til behandling af hyperkeratosiske hudsygdomme
ES2057004T3 (es) N-alcoxialquilamidas de hidroxiacidos y composiciones a base de las mismas para el tratamiento de la piel.
ES2038176T3 (es) Un procedimiento para la preparacion de derivados del naftaleno.
ES2162678T3 (es) Nuevos derivados diarilmetilideno furanicos, sus procedimientos de preparacion y sus utilizaciones en terapeutica.
ES2061218T3 (es) Composiciones farmaceuticas estabilizadas.
IT1254521B (it) Derivati della 2-ammino-tetralina attivi sul sistema cardiovascolare
IT7849712A0 (it) Derivati di 3/3-dicloro-2-azetidino ne ad attivita' anti-infiammatoria e procedimento di produzione
DK599986A (da) Terapeutisk middel i form af et hudplaster
BG32116A3 (bg) Метод за получаване на 4''-амино-олеандомицинови производни
IT1094215B (it) Pirrolo chinossalinoni e pirrolo benzodiazepinoni utili come agenti antiinfiammatori e antitrombotici e procedimento per prepararli
CR6693A (es) Pirazolo (4,3-e) diazepinas sustituidas novedosas, composiciones farmaceuticas que las contienen, su uso como productos medicinales y procesos para prepararlas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 488061

Country of ref document: ES